New documents have investigators questioning inconsistencies and omissions in data reporting in the PLATO trial, building on ...
A HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, or higher expression of HER2 proteins ...
The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...
Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...
As CEOs continue to digest the fallout of the murder of UnitedHealthcare CEO Brian Johnson, a billionaire backer of major ...
Shares of AstraZeneca PLC AZN inched up 0.28% to £105.68 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.12% to 8,311.76.
AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...
In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...
AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...
AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...
15h
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ...
AstraZeneca PLC ADR closed $20.28 below its 52-week high ($87.68), which the company achieved on August 30th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback